JUUL announced a tentative deal to pay nearly $440 million to settle a two-year, multi-state investigation into its underage marketing practices to attract young consumers to its addictive e-cigarettes. Evidence-based tobacco control is still critical.
Today the U.S. House of Representatives passed the Inflation Reduction Act, which includes several provisions that will reduce the costs of health care for millions of cancer patients and survivors.
Monica M. Bertagnolli, MD, will serve as the National Cancer Institute (NCI)’s new director, a role critical to ensuring ongoing innovation in oncology.
Today the U.S. Senate passed the Inflation Reduction Act, which includes several provisions that will reduce the costs of health care for millions of cancer patients and survivors.
Today the U.S. Senate Appropriations Committee released its FY 2023 spending bill that includes a $2 billion funding increase for the National Institutes of Health (NIH), including a $291 million funding boost for the National Cancer Institute (NCI).
The Health and Human Services Department released a proposed rule Monday expanding nondiscrimination protections for patients using federally funded health programs.
The American Cancer Society Cancer Action Network (ACS CAN) is pleased to announce the hire of a new vice president of federal affairs, and two new federal relations directors.
The U.S. Court of Appeals for the Fifth Circuit ruled in favor of the U.S. Food and Drug Administration (FDA) in the case of Triton Distribution v. FDA, upholding the agency’s marketing denial order (MDO) for Triton’s flavored e-cigarette products.
A new national poll conducted by a bipartisan team of researchers for ACS CAN found 8 in 10 (81%) voters agree that the government should protect people so that they don’t lose their coverage during high inflation and economic instability.
An article released today in JAMA Network Open details the potential benefits of using technology to increase patient participation in cancer clinical trials. In a survey of nearly 1,200 recent cancer patients and survivors, more than 80% said they would be willing to use remote technologies and tools in a trial.